Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Stephen Barat"'
Autor:
Lisa Long, Sherman Chu, Katyna Borroto-Esoda, Stephen Barat, Mahmoud A. Ghannoum, Rania Sherif, Thomas S. McCormick
Publikováno v:
Antimicrob Agents Chemother
Due to the increase of antifungal drug resistance and difficulties associated with drug administration, new antifungal agents for invasive fungal infections are needed. SCY-247 is a second-generation fungerp antifungal compound that interferes with t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31e45b4a3c397f0232ebf04f7ddd5513
https://doi.org/10.1128/aac.01988-20
https://doi.org/10.1128/aac.01988-20
Autor:
Mahmoud A. Ghannoum, Lisa Long, Stephen Barat, Katyna Borroto-Esoda, Thomas S. McCormick, Sherman Chu
Publikováno v:
Antimicrobial Agents and Chemotherapy. 65
Echinocandins are a first-line therapy for Candida infections through their ability to inhibit the synthesis of polymer β-(1,3)-d-glucan. However, there has been an emergence of multidrug-resistant fungal species necessitating the development of nov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::65303b0dbc9a2b6b0cbae7aa966b7b67
https://doi.org/10.1128/aac.01989-20
https://doi.org/10.1128/aac.01989-20
Publikováno v:
Antimicrob Agents Chemother
Candida auris has been shown to have a high risk of skin colonization in hospitalized patients, possibly contributing to nosocomial spread. In a guinea pig skin model, animals were evaluated for clinical appearance, tissue fungal burden, histology, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9d34164f4581caecc502d5a38238ec8
https://doi.org/10.1128/aac.00854-20
https://doi.org/10.1128/aac.00854-20
Autor:
Sherman, Chu, Lisa, Long, Thomas S, McCormick, Katyna, Borroto-Esoda, Stephen, Barat, Mahmoud A, Ghannoum
Publikováno v:
Antimicrob Agents Chemother
Echinocandins are a first-line therapy for Candida infections through their ability to inhibit the synthesis of polymer β-(1,3)-d-glucan. However, there has been an emergence of multidrug-resistant fungal species necessitating the development of nov
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9122d1dcc3eff9ef9241894be73c707e
https://pubmed.ncbi.nlm.nih.gov/33318003
https://pubmed.ncbi.nlm.nih.gov/33318003
Autor:
Matthew C. Zimmerman, Yanan Zhao, David Angulo, Brendan Prideaux, David S. Perlin, Annie Lee, Stephen Barat, Claire L. Carter, Véronique Dartois
Publikováno v:
Antimicrob Agents Chemother
Ibrexafungerp (IBX), formerly SCY-078, is a novel, oral and intravenous, semisynthetic triterpenoid glucan synthase inhibitor in clinical development for treating multiple fungal infections, including invasive candidiasis. Intra-abdominal candidiasis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e25e40ac0656b149444cb70074b51f4e
https://doi.org/10.1128/aac.02268-19
https://doi.org/10.1128/aac.02268-19
Autor:
Ethan Naing, Nkechi Azie, Bo Bo Win Maung, Ruta Petraitiene, Thomas J. Walsh, Stephen Barat, Katyna Borroto-Esoda, David Angulo, Povilas Kavaliauskas, Aspasia Katragkou, Vidmantas Petraitis
Publikováno v:
Antimicrob Agents Chemother
Ibrexafungerp (formerly SCY-078) is a semisynthetic triterpenoid and potent (1→3)-β-d-glucan synthase inhibitor. We investigated the in vitro activity, pharmacokinetics, and in vivo efficacy of ibrexafungerp (SCY) alone and in combination with ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da16e0a0351c642cfcd57adf99862e90
https://pubmed.ncbi.nlm.nih.gov/32179521
https://pubmed.ncbi.nlm.nih.gov/32179521
Autor:
Mahmoud A. Ghannoum, David Angulo, Christopher L. Hager, Katyna Borroto-Esoda, Stephen Barat, R. Wilson, Lisa Long, N. Isham
Publikováno v:
Antimicrobial Agents and Chemotherapy. 63
Ibrexafungerp (formerly SCY-078), a novel glucan synthase inhibitor with oral availability, was evaluated for activity against Candida glabrata . The susceptibility of clinical strains to ibrexafungerp was determined by microdilution and time-kill as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e9fc1cc079d6bf6d20f2933eda456fa6
https://doi.org/10.1128/aac.01510-19
https://doi.org/10.1128/aac.01510-19
Publikováno v:
American Journal of Obstetrics and Gynecology. 221:689-690
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c7b5b41294bf878f39b24ec2b324d1ca
https://doi.org/10.1016/j.ajog.2019.10.048
https://doi.org/10.1016/j.ajog.2019.10.048
Autor:
Yan Chun Zhu, Sudha Chaturvedi, David Angulo, Katyna Borroto-Esoda, Stephen Barat, Vishnu Chaturvedi
We report low MIC50 of Ibrexafungerp (SCY-078) for 102 Candida auris clinical and surveillance isolates from outbreak in New York. The group included C. auris with a variable resistance to antifungal drugs. Five pan-resistant C. auris isolates were s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7fdb0cfc217f00789ad13be334007442
Autor:
N. Isham, Steve Wring, David Angulo, Katyna Borroto-Esoda, Lisa Long, Stephen Barat, Emily L Larkin, Mahmoud A. Ghannoum
Publikováno v:
Antimicrobial Agents and Chemotherapy. 63
Ibrexafungerp (IBX) (formerly SCY-078) is a novel glucan synthase inhibitor whose oral availability is being evaluated for efficacy against vulvovaginal candidiasis (VVC). Bioavailability and in vitro activity are important efficacy indicators, but a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2681493c90d5ce4c1a79b96b4377cdd3
https://doi.org/10.1128/aac.02611-18
https://doi.org/10.1128/aac.02611-18